NCT07499999 (BabyTEARS) is a Phase 2 clinical trial of Exemestane in Breast Cancer, sponsored by Dana-Farber Cancer Institute.

Who is sponsoring NCT07499999?

NCT07499999 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT07499999?

Interventions in NCT07499999: Exemestane, Tamoxifen.

What condition does NCT07499999 study?

NCT07499999 studies Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation.

Is NCT07499999 still recruiting?

NCT07499999 is currently not yet recruiting. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT07499999: BabyTEARS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

Not yet recruiting Phase 2 Last updated 30 March 2026

What this trial tests

Phase 2 trial testing Exemestane in Breast Cancer in 140 participants. Not yet recruiting.

Timeline

9 September 2026

Primary endpoint
31 August 2027

31 August 2028

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	140
Start date	9 September 2026
Primary completion	31 August 2027
Estimated completion	31 August 2028
Sites	2 locations across United States

Drugs / interventions tested

Exemestane (exemestane) — full drug profile →
Tamoxifen — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Ductal Carcinoma — all drugs for Ductal Carcinoma →
Estrogen-receptor-positive Breast Cancer — all drugs for Estrogen-receptor-positive Breast Cancer →
Atypical Lobular Hyperplasia — all drugs for Atypical Lobular Hyperplasia →

Sponsor

Dana-Farber Cancer Institute

Who can join

Eligibility, female only, with Breast Cancer or Ductal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer. The names of the study drugs involved in this study are: * Exemestane (a type of steroidal aromatase inhibitor) * Tamoxifen (a type of selective estrogen receptor modulator)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Exemestane

Trials testing the same drug.

NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
NCT06979596 — A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) · Phase 2 · recruiting
NCT07062965 — A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, · Phase 3 · recruiting
NCT06630325 — A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovaria · Phase 2 · terminated
NCT06223698 — Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer · Phase 3 · not yet recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting
NCT07465276 — Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07499999 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07499999.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing